5-Amino Oral (50 mg)

5-Amino Oral (50 mg) is an oral-form research compound used to investigate systemic NNMT inhibition, methyl-donor dynamics, and whole-body metabolic regulation in animal and cellular models.

Because NNMT is widely distributed across liver, adipose tissue, kidneys, and certain cancers, oral delivery is used in preclinical environments to study bioavailability, systemic metabolic flux, and pharmacodynamic responses.

Mechanistic Properties in Oral Research Models

Experimental oral dosing models show:

• Systemic reduction in 1-MNA levels (NNMT activity marker)

• Altered nicotinamide → NAD⁺ conversion rates

• Increased expression of mitochondrial oxidative genes

• Possible effects on glucose and lipid handling in metabolic tissues

• Modulation of inflammatory and methylation pathways

Oral NNMT-inhibition studies have been explored for insights into hepatic metabolism, adipocyte biology, methylation balance, and aging-related NAD⁺ decline.

Metabolic and Epigenetic Research Applications

Researchers use oral NNMT inhibitors to study:

• Obesity and diet-induced metabolic dysfunction models

• Aging-associated NAD⁺ depletion

• Hepatic fat metabolism and mitochondrial oxidation

• Epigenetic regulation via SAM-dependent methyltransferases

• Cancer cell metabolic remodeling

These studies highlight NNMT’s role at the crossroads of epigenetics, metabolism, and energy homeostasis.

Research Use Only — Important Notice

• Not for human consumption

• For controlled laboratory research only

• Not a therapeutic substance

• All descriptions summarize preclinical findings only

References – Oral NNMT Inhibition

1. Kannt A et al. Discovery of potent small-molecule NNMT inhibitors and metabolic profiling in vivo.
   https://pubmed.ncbi.nlm.nih.gov/31495893/

2. Roberti A et al. NNMT and methylation metabolism in metabolic disease models.
   https://pubmed.ncbi.nlm.nih.gov/31953484/

3. Hong S et al. Systemic influence of NNMT inhibition on methylation and NAD⁺ pathways.
   https://pubmed.ncbi.nlm.nih.gov/33896442/

📌 SLU-PP (500 mg)

(SLU-PP-332 / Estrogen-Related Receptor Agonist Research)

SLU-PP refers to a class of small-molecule experimental activators of estrogen-related receptors (ERRα/ERRγ)—key nuclear receptors involved in mitochondrial biogenesis, oxidative metabolism, and energy expenditure.

ERR pathways regulate:

• Mitochondrial protein transcription

• Fatty acid oxidation

• Oxidative phosphorylation

• ATP generation

• Adaptive thermogenesis

• Muscle metabolic remodeling

SLU-PP molecules (e.g., SLU-PP-332) have been used to probe mitochondrial activation and endurance-type metabolic profiles.

Specifications

• Synonyms: SLU-PP, SLU-PP-332 analogs, ERR modulator

• Class: Nuclear receptor agonist (ERRα/ERRγ)

• Research Focus: Mitochondrial function, oxidative metabolism, metabolic disease modeling

Mechanism of Action — ERR Activation

Experimental ERR agonists such as SLU-PP have been found to:

• Increase expression of PGC-1α–dependent mitochondrial genes

• Enhance fatty acid oxidation and oxidative phosphorylation (OXPHOS)

• Amplify mitochondrial respiratory capacity

• Shift cellular metabolism toward endurance-like phenotypes

In vitro exposure increases transcription of genes encoding:

• Electron transport chain components

• Mitochondrial ribosomal proteins

• β-oxidation enzymes

• TCA cycle enzymes

These mechanisms make SLU-PP compounds valuable tools in mitochondrial and exercise-mimetic research.

Experimental Findings in Metabolic Research

SLU-PP–based ERR activation models show:

• Increased mitochondrial DNA content

• Greater oxygen consumption rate (OCR)

• Improved mitochondrial coupling efficiency

• Altered lipid metabolism and substrate utilization

• Potential insight into diabetes, metabolic syndrome, and endurance-adaptation biology

Recent work demonstrated that ERR agonism enhances mitochondrial energy capacity in multiple tissue types, including skeletal muscle, liver, and cardiac cells.

Research Use Only — Important Notice

• Not for human or veterinary use

• Not for therapeutic, diagnostic, or cosmetic applications

• For controlled in vitro or animal research environments only

References – SLU-PP (ERR Agonist Research)

1. Bi P et al. Activation of ERRγ enhances oxidative metabolism and mitochondrial gene programs.
   https://pubmed.ncbi.nlm.nih.gov/26092696/

2. Misra J et al. ERRα/γ regulate energy metabolism and mitochondrial biogenesis.
   https://pubmed.ncbi.nlm.nih.gov/23211537/

3. Luo J et al. ERR pathway control of metabolic remodeling in experimental models.
   https://pubmed.ncbi.nlm.nih.gov/23582332/

4. Pulinilkunnil T et al. Nuclear receptor ERRγ as a regulator of cardiac mitochondrial metabolism.
   https://pubmed.ncbi.nlm.nih.gov/21709061/